Stocks · News reference
MDxHealth reports Q2 sales growth, mixed earnings and reaffirmed 2026 revenue guidance as tissue test volumes rise.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target, HSBC raised TX target, Rothschild upgraded EFX, HC Wainwright lowered COCH target, BTIG cut MDXH target, Baird raised ROST target.
Read original at benzingaBTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.
Read original at benzingaHIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings, Expion360, Skye Bioscience, Julong Holding, FIEE Inc, and Keel Infrastructure. Losers include Generation Income Properties, Barfresh Food Group, iTonic Holdings, Akanda Corp, and Reservoir Media.
Read original at benzingaLake Street analyst Thomas Flaten maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $5 to $3.
Read original at benzinga